Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07429253

Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients

This study aims to compare the effectiveness of secretome injection and intradermal platelet-rich plasma (PRP) injection on hair density and the terminal-to-vellus hair ratio in patients with androgenetic alopecia at Prof. Dr. I.G.N.G. Ngoerah General Hospital.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Androgenetic Alopecia Alopecia Hair Diseases Hypotrichosis Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Skin Diseases Skin and Connective Tissue Diseases

Age range

25 year–59 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Prof. dr. I.G.N.G. Ngoerah Central General Hospital

Denpasar, Bali, 80113, Indonesia

Location status: Recruiting

Location contact

Dr. dr. I Gusti Nyoman Darmaputra, Sp.D.V.E., Subsp. O.B.K., FINS

CONTACT

[email protected]

+628124644451

Dr. dr. I Gusti Nyoman Darmaputra, Sp.D.V.E., Subsp. O.B.K., FINS

PRINCIPAL_INVESTIGATOR

About this study

This research is an experimental study with a randomized controlled clinical design involving two intervention groups: one receiving secretome injections and the other receiving intradermal platelet-rich plasma injections. Evaluations are conducted by measuring hair density and the terminal-to-vellus hair ratio before and after treatment using trichoscopy/dermoscopy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Hamilton-Norwood grades II to VI, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital.
  • Female patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Ludwig grades I to III, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital.
  • Female patients who are not currently pregnant or breastfeeding.
  • Patients who have discontinued anti-androgen medication and minoxidil for at least 1 month prior to the procedure.
  • Patients with no known allergies to secretome components and/or materials used in the platelet-rich plasma (PRP) preparation process.
  • Patients who are proficient in Indonesian and willing to provide written informed consent.

Exclusion criteria

  • Participants who are unable to speak or understand Indonesian and/or are unwilling to provide written informed consent.
  • Patients presenting with types of hair loss other than androgenetic alopecia.
  • Patients currently undergoing therapy with 5-alpha reductase inhibitors.
  • Patients who have received intradermal corticosteroid injections to the scalp within at least 6 months prior to the study.
  • Patients with active infections and/or active dermatitis on the scalp.
  • Patients with a known history of allergy to secretome components and/or materials used in the platelet-rich plasma (PRP) preparation process.
  • History of hypertrophic scarring or blood clotting (coagulation) disorders.
  • Patients unable to complete the research procedures in their entirety.

Treatment and study plan

Secretome

Biological

UC-MSC secretome was injected intradermally into the scalp at the alopecia site, with injections spaced 1 cm apart and administered every 2 weeks for 8 weeks

Platelet-Rich Plasma (PRP) Injections

Biological

The centrifuged plasma solution was injected intradermally into the scalp at the alopecia site, with 0.1 ml per injection point spaced 1 cm apart, administered every 2 weeks for 8 weeks

Primary outcomes

  1. Terminal-to-Vellus Hair Ratio

    Time frame: Baseline (before treatment), post-intervention (at 8 weeks), and during follow-up visits (months 3, 6, and 9)

    The ratio of terminal hair (thick, pigmented hair, diameter >40 micrometer) to vellus hair (fine hair, diameter <30 micrometer) in areas of androgenetic alopecia

  2. Hair density

    Time frame: Baseline (before treatment), post-intervention (at 8 weeks), and during follow-up visits (months 3, 6, and 9)

    The number of hairs per specific scalp area was measured in hairs/cm²

Sponsors and collaborators

Lead sponsor

PT. Prodia Stem Cell Indonesia

Industry

Collaborators

  • RS Prof. Dr. I.G.N.G Ngoerah

Registry information

Official study title

Comparative Effectiveness of Secretome Injection and Intradermal Platelet-Rich Plasma Injection on Hair Density and Terminal-to-Vellus Hair Ratio in Patients With Androgenetic Alopecia at Prof. Dr. I.G.N.G. Ngoerah General Hospital

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Feb 24, 2026
Registry last updated
Feb 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.